Related Topics News -

     
 Title only   |   Print    Next page > 
     
中國抗體SM17治療特應性皮炎中國2期臨床完成首例患者給藥

2026-04-01T  
中國抗體:SM17完成中國給藥途徑轉換1期橋接研究

2026-03-25T  
《業績》中國抗體全年虧損收窄至1.05億人民幣

2026-03-24T  
中國抗體SM17治療炎症性腸病臨床試驗申請獲批

2026-02-24T  
中國抗體-B發表SM17臨床前研究 凸顯治療CRSwNP和IPF潛力

2026-02-20T  
中國抗體SM17針對炎症性腸病新藥研究申請已獲受理

2025-12-11T  
中國抗體SM17皮下注射劑實驗完成首個受試者給藥

2025-10-14T  
《業績》中國抗體中期虧損收窄至4,982萬人民幣

2025-08-31T  
中國抗體與中山大學香港高等研究院訂立全面戰略合作協議 開展為期三年合作

2025-08-12T  
中國抗體折讓16.12%發新股 集資3.7億元

2025-07-22T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.